Rigor Reviewed

Rigor-Reviewed Manuscript

Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.

Name: Αlpha¹ Rigor Record — Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Item: Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.
Rating: 94
Author: Αlpha¹

Borowsky B, Ramos H, Caputo A, Hartmann A, Faller T, Peters T, Sui Y, Liu F, Meadowcroft M, David OJ, Laisney M, Kinhikar A, Marder KS, Tabrizi SJ, Landwehrmeyer GB, Leavitt BR

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.75★ (Adequate), 0 critical, 5 high issues for “Oral splicing modulator branaplam in Huntington's disease: a phase 2 randomized controlled trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.75 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsOverstated claim−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.29.0Source: full text

Not verified in this report

References were found (36) but none could be checked — every lookup failed or lacked a DOI.
No reported statistical tests were found to recompute.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced4 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions overstated beyond the evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Copyediting1

Wording, consistency and formatting errors that need correcting before submission.

Wording or formatting errors that need correctingAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 2b trial of branaplam in Huntington's disease, with strong scientific premise, robust design, and thorough ethical and reporting practices. The main weaknesses are minor reporting gaps: effect sizes are reported with SEs rather than CIs, the bespoke PK-PD modeling code is not shared, and several copyedit issues (unit inconsistencies, broken cross-references, typos) need correction.

This synthesis is based on two independent reviewer runs that largely agreed, with a divergence on data code availability (pass vs. warn) that was resolved by weighing the evidence for the missing PK-PD code. The statistics verification component could only recompute a subset of reported tests (none with test statistics/CIs), so the absence of detected errors does not confirm overall statistical correctness. The citation component found no retracted or unresolved references.

4 major claims checked against the paper's own evidence: 1 not fully backed by the presented evidence (unsupported or overstated).

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

Prior work on HTT lowering and branaplam's mechanism is extensively cited (references 1–22). The rationale linking HTT lowering to disease modification is explicit, and the paper acknowledges limitations of prior safety observations (e.g., neurotoxicity in dogs) and addresses them through monitoring and study design.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The premise is well-established: lowering mutant huntingtin is a promising strategy, and branaplam's mechanism is clearly described with extensive prior work cited.

Evidence

paraphrase[Introduction, paragraph 1–3]

“Branaplam was originally developed as a treatment for spinal muscular atrophy (SMA), in which it increases the amount of functional survival motor neuron protein produced by the SMN2 gene by modifying its mRNA splicing.”

paraphrase[Introduction, paragraph 3]

“Lowering the expression of total or mutant HTT in the brain is associated with a corresponding decrease in HTT levels in the cerebrospinal fluid (CSF), and a reduction of up to 40% in CSF mHTT has been shown to be safe and well tolerated in humans.”

paraphrase[Introduction, paragraph 4]

“Modulation of mRNA splicing nevertheless carries risks associated with off-target effects.”

PASSReviewer 2· 90% conf

The paper establishes a thorough scientific foundation, citing the HD/mHTT literature, branaplam's mechanism, and prior preclinical/clinical data, with an explicit rationale linking mHTT lowering to expected clinical benefit.

Evidence

direct quote[Introduction, paragraph 3]

“Branaplam had been shown to lower mHTT levels in neuroblastoma cells of individuals with HD and in an HD mouse model (BacHD)”